<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02866838</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC 2016-01251</org_study_id>
    <nct_id>NCT02866838</nct_id>
  </id_info>
  <brief_title>Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist</brief_title>
  <acronym>TICH-NOAC</acronym>
  <official_title>Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist Oral Anticoagulants (NOAC) With Tranexamic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Novel, non-vitamin K antagonist oral anticoagulants (NOAC) target selected players in the
      coagulation cascade as the direct thrombin inhibitor dabigatran and the factor Xa-inhibitors
      apixaban and rivaroxaban. Intracerebral hemorrhage (ICH) is the most feared complication of
      NOAC treatment (NOAC-ICH).

      Outcome of NOAC-ICH can be devastating and is a major cause of death and disability. There is
      no proven treatment for NOAC-ICH. Hematoma expansion (HE) is associated with unfavorable
      outcome. Tranexamic acid (TA) is an anti-fibrinolytic drug that is used in a number of
      bleeding conditions other than ICH.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematoma expansion</measure>
    <time_frame>up to 27 hours</time_frame>
    <description>Change in ICH-volume between baseline CT and follow-up-CT at 24 ± 3 hours of 33% relative or 6ml absolute increase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale (mRS) 0-4 at month 3;</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS 0-3 at month 3;</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical shift in mRS at month 3</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality due to any cause at month 3</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>baseline until discharge from hospital (stay at hospital lasts on an average of 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute ICH growth volume by 24 ± 3 hours, adjusted for baseline ICH volume</measure>
    <time_frame>up to 27 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic HE defined as HE and additionally a neurological deterioration of NIHSS &gt;4 points or Glasgow Coma Scale (GCS) &gt;2 points</measure>
    <time_frame>up to 27 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of major thromboembolic events (myocardial infarction, ischemic stroke, pulmonary embolism - safety endpoints)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of neurosurgical interventions (including craniectomy, external ventricular drain (EVD), hematoma evacuation)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous tranexamic acid: 1g loading dose given as 100 mls infusion over 10 minutes, followed by another 1g in 250 mls infused over 8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline 0.9% given in identical dosage as experimental</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9%</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute intracerebral hemorrhage (symptom onset &lt;12h)

          -  Prior treatment with a novel direct oral anticoagulant (apixaban, dabigatran, edoxaban
             or rivaroxaban; last intake &lt;48hours or proven NOAC activity by relevant coagulation
             assays)

          -  Age &gt;18 years, No upper age limit

          -  Informed consent has been received in accordance to local ethics committee
             requirements

        Exclusion Criteria:

          -  Severe pre-morbid disability (modified Rankin scale &gt;4)

          -  Anticoagulation with Vitamin K antagonists (VKA) (recent intake)

          -  Secondary intracerebral hemorrhage (e.g. arteriovenous malformation (AVM), tumor,
             trauma) Note it is not necessary for investigators to exclude underlying structural
             abnormality prior to enrolment, but where an underlying structural abnormality is
             already known, these patients should not be recruited.

          -  Glasgow coma scale &lt;5

          -  pregnancy

          -  Planned neurosurgical hematoma evacuation within 24 hours (before follow-up imaging)

          -  Pulmonary embolism/deep vein thrombosis within the last 2 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Lyrer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stroke Center and Neurology, University Hospital Basel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Engelter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stroke Center and Neurology, University Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Seiffge, MD</last_name>
    <phone>0041-61-32 87278</phone>
    <email>david.seiffge@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marina Maurer</last_name>
    <phone>0041-61-2565030</phone>
    <email>marina.maurer@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stroke Center, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Maurer</last_name>
      <phone>0041-61-2565030</phone>
      <email>marina.maurer@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Nils Peters, MD</last_name>
      <email>nils.peters@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Nils Peters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Seiffge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tranexamic acid</keyword>
  <keyword>NOAC</keyword>
  <keyword>Direct Oral Anticoagulant (DOAC)</keyword>
  <keyword>Direct oral anticoagulants</keyword>
  <keyword>Non-Vitamin K antagonist oral anticoagulants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

